Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis
Top Cited Papers
Open Access
- 15 March 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 58 (4), 1215-1224
- https://doi.org/10.1002/hep.26387
Abstract
People detained in prisons and other closed settings are at elevated risk of infection with hepatitis C virus (HCV). We undertook a systematic review and meta-analysis with the aim of determining the rate of incident HCV infection and the prevalence of anti-HCV among detainees in closed settings. We systematically searched databases of peer-reviewed literature and widely distributed a call for unpublished data. We calculated summary estimates of incidence and prevalence among general population detainees and detainees with a history of injection drug use (IDU), and explored heterogeneity through stratification and meta-regression. The summary prevalence estimates were used to estimate the number of anti-HCV positive prisoners globally. HCV incidence among general detainees was 1.4 per 100 person-years (py; 95% confidence interval [CI]: 0.1, 2.7; k = 4), and 16.4 per 100 py (95% CI: 0.8, 32.1; k = 3) among detainees with a history of IDU. The summary prevalence estimate of anti-HCV in general detainees was 26% (95% CI: 23%, 29%; k = 93), and in detainees with a history of IDU, 64% (95% CI: 58%, 70%; k = 51). The regions of highest prevalence were Central Asia (38%; 95% CI 32%, 43%; k = 1) and Australasia (35%; 95% CI: 28%, 43%; k = 9). We estimate that 2.2 million (range: 1.4-2.9 million) detainees globally are anti-HCV positive, with the largest populations in North America (668,500; range: 553,500-784,000) and East and Southeast Asia (638,000; range: 332,000-970,000). Conclusion : HCV is a significant concern in detained populations, with one in four detainees anti-HCV-positive. Epidemiological data on the extent of HCV infection in detained populations is lacking in many countries. Greater attention towards prevention, diagnosis, and treatment of HCV infection among detained populations is urgently required. (Hepatology 2013;58:1215–1224)Keywords
This publication has 38 references indexed in Scilit:
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject DrugsThe Journal of Infectious Diseases, 2011
- HIV and Hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysisBMC Public Health, 2010
- Incarceration experiences among a community-recruited sample of injection drug users in Bangkok, ThailandBMC Public Health, 2009
- Prevalence and Correlates of Hepatitis C Infection among Male Injection Drug Users in Detention, Tehran, IranJournal of Urban Health, 2009
- The harm inside: Injection during incarceration among male injection drug users in Tijuana, MexicoDrug and Alcohol Dependence, 2009
- Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and PlaceAmerican Journal of Epidemiology, 2008
- The HCV Synthesis Project: Scope, methodology, and preliminary resultsBMC Medical Research Methodology, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003